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Inhibitors of apoptosis proteins (IAPs) are key intrinsic regulators of caspases-3 and -7. During ischemia, IAP-2 is upregulated dramatically,
while the other IAPs show little or no change. To test whether IAP-2 prevents cardiac apoptosis and injury following ischemia/reperfusion, we
generated a line of transgenic mice that carried a mouse IAP-2 transgene. High levels of mouse IAP-2 transcripts and 70 kDa IAP-2 were expressed
in the hearts of transgenic mice, whereas IAP-1 and XIAP levels remained the same. Immunohistochemical studies revealed more intense staining of
IAP-2 in the myocytes of transgenic mouse hearts. To assess the role of IAP-2 in I/R injury, the transgenic mice were subjected to ligation of the left
descending anterior coronary artery ligation followed by reperfusion. The infarct sizes, expressed as the percentage of the area at risk, were
significantly smaller in the transgenic mice than in the non-transgenic mice (30±2% vs. 44±2%, respectively, P<0.05). This protection was
accompanied by a decrease of the serum level of troponin I in the transgenic mice. IAP-2 transgenic hearts had significantly fewer TUNEL-positive
cardiac cells, which indicated an attenuation of apoptosis. Our results demonstrate that overexpression of IAP-2 renders the heart more resistant to
apoptosis and I/R injury.
© 2007 Elsevier B.V. All rights reserved.Keywords: Caspases; Inhibitor of apoptosis proteins; Ischemia/reperfusion injury; Heart1. Introduction
Apoptosis has been implicated in a number of cardiac
diseases such as heart failure [1–3], anthracycline-induced
cardiotoxicity [4–6], and overstretching of myocytes [7].
Myocardial ischemia/reperfusion (I/R) also leads to cell death,
which is believed to occur through apoptosis and necrosis
[8–11]. Kajstura et al. [12] showed that apoptosis was the
predominant mode of cardiac cell death induced by coronary
artery occlusion.
There are three main pathways leading to apoptosis [13–15].
The extrinsic apoptotic pathway is mediated by the death recep-
tor Fas/FasL and involves the activation of caspase-8. The⁎ Corresponding author. Tel.: +1 423 926 1171x7238; fax: +1 423 979 3408.
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doi:10.1016/j.bbamcr.2007.01.007intrinsic pathway involves mitochondrial dysfunction, cyto-
chrome c release, and activation of caspase-9. The third apop-
tosis pathway is activated by ER stress and involves caspase-12.
Caspases are the major players for the execution of apoptosis
[16,17]. They can be categorized into initiator caspases (-2, -8,
-9, -10, and -12) and executioner caspases (-3, -6, and -7).
Initiator caspases undergo autoproteolytic activation, while
executioner caspases are responsible for dismantling cellular
structure. Activation of various caspases can be blocked by
inhibitor of apoptosis proteins (IAPs). IAP family members are
characterized by the presence of one or more BIR domains in
their sequence and by their ability to bind and inhibit caspases.
Eight IAP members have been discovered so far, namely IAP-1,
IAP2, XIAP, ILP2, MLIAP, NIAP, survivin, and Bruce [18–24].
Recent studies demonstrate that XIAP, IAP-1, and IAP-2 can
prevent the proteolytic processing of procaspases-3, -6, and -7
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pase-9 [25].
IAP-2 has been detected in the heart, but its physiological
role is not clear [26]. To further understand the role of IAP-2 in
myocardial I/R injury and apoptosis in a more physiological
setting, an animal model that overexpresses IAP-2 was needed.
Toward this end, our experiments were designed to achieve the
following goals: (1) to generate transgenic mice bearing extra
copies of cloned mouse IAP-2 cDNAs under the transcriptional
control of a mouse α-myosin heavy chain promoter to allow
high-level expression of transgenes in the heart; (2) to determine
the levels of expressed IAP-2 in the hearts of these animals; and
(3) to elucidate the effect of IAP-2 overexpression on ischemia/
reperfusion injury and apoptosis.
2. Materials and methods
2.1. Generation of IAP-2 transgenic mice
An IAP-2 expression vector was constructed by initially inserting the SacI to
SalI fragment of clone 22 (kindly provided by Dr. J. Robbins, University of
Cincinnati, Cincinnati, OH), which contains the sequence from the last intron of
the mouse β-myosin heavy chain gene to exon 3 of the α-myosin heavy chain
gene, into SacI to SalI sites in plasmid pMSG (Amersham Pharmacia Biotech,
Inc., Piscataway, NJ). BamHI digestion of the resultant plasmid allowed isolation
of the DNA fragment containing SV40 early splicing and polyadenylation sites
downstream from the mouse α-myosin heavy chain sequence. This DNA
fragment was then inserted into the BamHI site of plasmid pKS-S, a modified
pKS vector (Stratagene, La Jolla, CA) in which the SalI site was destructed by
insertion of an SfiI linker, to generate plasmid pMHC. The full-length mouse
IAP-2 cDNA, which had previously been flanked by SalI sites using linker
ligation, was subsequently inserted into the SalI site in plasmid pMHC. The
entire expression sequence was isolated by ClaI plus NotI digestion of the
resultant plasmid, and it was utilized in the generation of transgenic mice using
fertilized mouse eggs isolated from mating of B6C3 F1 hybrid mice according to
standard procedures.
2.2. Analysis of in vivo cardiac function
Mice were anesthetized with tribromoethanol (275 mg/kg, i.p.). Each
mouse was intubated with a 22-gauge soft catheter and ventilated with a rodent
ventilator (Columbus Instruments International Corp., Columbus, OH) at a
tidal volume of 0.3–0.5 ml and a respiratory rate of 110–120 breaths/min.
After left thoracotomy, the pericardium was dissected to expose the heart. A
26-gauge needle connected to a pressure transducer was introduced into the
left ventricle after an apical stab to measure the left ventricular pressure.
Cardiac function parameters, including LVEDP (left ventricular end-diastolic
pressure), LVESP (left ventricular end-systolic pressure), ±dP/dt (first
derivatives of left ventricular pressure over time), were analyzed with a
SonoSoft data acquisition and analysis system (SonoMetrics Corp., London,
Ontario).
2.3. Microarray analysis
Total RNA was extracted from the hearts of nontransgenic and transgenic
mice using TRI REAGENT LS (Molecular Research Center, Cincinnati, OH).
Superarray analysis was carried out according to manufacturer's instructions
(Superarray, Inc., Frederick, MD). cDNA probes were labeled with Ampolabel-
ing-LPR kit in the presence of 5 μg of RNA and biotin-16-dUTP. Labeled probes
were hybridized to mouse apoptosis GEArray Q series membranes. After
extensive washing, the chemiluminescence signals on the membranes were
exposed to X-ray films. Quantification was performed with optimally exposed
films and standardized against the housekeeping gene GAPDH using the
GEarray Analysis Suite.2.4. Immunoblot analysis of IAP-1, IAP-2, and XIAP
Hearts from nontransgenic and transgenic animals were homogenized in
a buffer containing 20 mM Tris–HCl (pH 7.8), 137 mM NaCl, 15%
glycerol, 1% Triton X-100, 2 μg/ml each of leupeptin, aprotinin, and
pepstatin, 2 mM benzamidine, 20 mM NaF, 10 mM sodium pyrophosphate,
1 mM sodium vanadate, 25 mM beta-glycerophosphate, and 0.1 mM phe-
nylmethylsulfonylfluoride. Homogenates were heated at 95 °C for 10 min,
passed through a 23 gauge needle five times, and centrifuged at 12,000×g
for 10 min. Protein concentration of the supernatant was determined by
Biorad dye binding assay. Aliquots containing 100 μg were electrophoresed
on 12% SDS-PAGE and transferred onto nitrocellulose membranes. Immu-
noblot analysis was carried out by incubating the membrane with IAP-1,
IAP-2 (Santa Cruz Biotechnology, Santa Cruz, CA), or XIAP antibodies
(BD-Pharmingen, San Diego, CA). Horseradish peroxidase conjugated goat
anti-rabbit or anti-mouse antibodies were then added. Blot was developed
using ECL detection system (Amersham Biosciences, Piscataway, NJ) and
exposed to X-ray films.
2.5. Immunohistochemistry
Paraffin-embedded myocardial sections (5 μm) were mounted on superfrost
slides and dried at 37 °C overnight. Heart specimens were subjected to antigen
retrieval by heating in 10 mM citrate (pH 6.0) in a microwave oven at 100%
power for 3.5 min and 50% power for 8 min. Immunostaining was carried out
with a rabbit IAP-2 antibody (R&D Systems, Minneapolis, MN) at 4 °C
overnight. Antigen–antibody complexes were detected by the Super-sensitive
alkaline phosphatase kit (BioGenex, San Ramon, CA), using Fast Red as a
chromogen. Hematoxylin was used as a counterstain.
2.6. Regional ischemia in vivo
Mice weighing 25–30 g were anesthetized with tribromoethanol (275 mg/
kg, i.p.). A 22-gauge soft catheter was inserted 5–8 mm from the larynx, and the
mice were ventilated with room air (a tidal volume of 0.3–0.5 ml) using a rodent
respirator (Columbus Instruments International, Columbus, OH) set at 110–120
beats/min. Left anterior descending coronary artery (LAD) ligation was per-
formed as described previously [27]. After 50 min of LAD ligation, the heart
was reperfused for 4 h.
Mice were anesthetized with tribromoethanol (275 mg/kg, i.p.), and hearts
were perfused as Langendorff preparations for 5 min. The left coronary artery
was re-occluded, and 1% Evans blue was infused into the aorta and coronary
arteries to determine the area at risk. Hearts were transversely cut into 5 sections,
with one section made at the site of the ligature. Macroscopic staining with 1%
triphenyltetrazolium chloride (Sigma Chemical Co., St. Louis, MO) in phos-
phate-buffered saline was used to quantitate the infarct sizes as described
previously [27]. The area at risk was expressed as the percentage of the left
ventricle, and the area of infarct was expressed as the percentage of the area at
risk as described [27].
2.7. Cardiac troponin I release
Although LDH activity has been used as a biomarker of cardiac injury, it is
not tissue-specific and the enzyme activity is rather unstable upon freezing and
thawing. As a result, an ELISA kit (Life Diagnostics, Inc., West Chester, PA)
was used to assay the plasma levels of cardiac troponin I, which has been shown
to be a more sensitive and specific biomarker of cardiac injury. Results were
expressed as ng/ml.
2.8. TUNEL assays
After 50 min of LAD ligation and 4 h of reperfusion, hearts were removed,
and a 2 mm section near the middle part of the area at risk was sliced, fixed in
4% formalin solution and embedded in paraffin. Myocardial sections (5 μm)
were mounted on superfrost slides and dried at 37 °C overnight. Immunohis-
tochemical procedures for detecting apoptotic cardiomyocytes were performed
Fig. 1. IAP-2 mRNA is overexpressed in the transgenic mouse heart. RNAwas
isolated from the hearts of nontransgenic and transgenic animals. Gene array
analysis was performed with mouse apoptosis Superarray Q series membranes
as described in Materials and methods. The position of IAP-2 and GAPDH is
marked by arrows.
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previously [27]. In this procedure, nuclei undergoing apoptosis were stained
blue. Nuclear Fast Red was used as a counterstain. TUNEL-positive myocytes
were determined by randomly counting 10 fields of approximately 1000 nuclei.
Myocyte nuclei are characterized by their size, shape, and location. Counting
was performed in a blinded fashion. The index of apoptosis was then
determined (i.e., number of apoptotic myocytes / total number of myocytes
counted×100).
2.9. Statistical analysis
Statistical analysis was performed by the Instat software. Significance of
differences between means was established by the Student's t test. Results were
expressed as means±SEM. P <0.05 was considered significant.
3. Results
We generated a line of transgenic mice that carried a mouse
IAP-2 transgene under the control of a mouse α-myosin heavy
chain promoter. Table 1 summarizes the basal hemodynamic
indices (HR, LVEDP, LVESP, and ±dP/dt) of the nontransgenic
and transgenic mice. At the age of 3–4 months, there were no
differences in heart weight, body weight, heart weight/body
weight or the basal cardiac function between the nontransgenic
and transgenic mice.
We performed a detailed gene expression study with the
offspring of the founder mouse. Total heart RNA was isolated
from nontransgenic or transgenic animals and subjected to gene
array analysis using Superarray mouse apoptosis Q-series
membranes. This allowed us to study the expression of 96
mouse apoptosis-related genes. There were a few genes that
were upregulated or downregulated in the IAP-2 transgenic
heart. The most apparent change was the upregulation of IAP-2
mRNA by 2.5-fold (Fig. 1).
We next determined IAP-2 protein expression by Western
blot analysis. Our results showed that the 70 kDa IAP-2 was
highly expressed in the transgenic heart (Fig. 2). Densitometric
analysis demonstrated a 2.3-fold increase of IAP-2 after
standardization with actin. Overexpression of IAP-2 did not
induce any changes in the expression of IAP-1 or XIAP (Fig. 2).
Immunoreactivity of IAP-2 demonstrated that it was strongly
expressed in the myocytes of transgenic hearts, as demonstratedTable 1
Basal cardiac function of nontransgenic and transgenic mice
Parameter Nontransgenics Transgenics
Heart Rate (beats/min) 364±10 363±21
+dP/dt (mm Hg/s) 2899±75 3381±477
−dP/dt (mm Hg/s) 2329±105 2565±191
LVDP (mm Hg) 81±1.7 95±4
LVEDP (mm Hg) 3.8±0.7 3.0±0.7
Heart wt, mg 86.4±2.3 87.2±4.9
Body wt, g 32±2.5 29±1.0
Heart wt/body wt (mg/g) 2.8±0.2 3.0±0.2
In vivo cardiac functionwasmeasured by the SonoMetrics system as described in
Materials and methods. All values are means±SEM of 5–6 hearts. Cardiac
functions are defined as: HR, heart rate, dP/dt, maximum rate of pressure
development; LVDP, left ventricular developed pressure; LVEDP, left ventricular
end-diastolic pressure.by diffused cytoplasmic staining. Endothelial cells or smooth
muscle cells did not show immunoreactivity to IAP-2 antibody.
There was significantly less IAP-2 staining in the nontransgenic
heart (Fig. 3).
To study the effect of IAP-2 overexpression on regional I/R
injury in vivo, mice were subjected to 50 min of LAD ligation
followed by 4 h of reperfusion. Fig. 4A shows a representative
TTC staining pattern of nontransgenic and transgenic hearts.
Infarcted areas appear pale, whereas viable tissues stain red.
The area at risk, expressed as the percentage of the left
ventricle (LV) between the nontransgenic and transgenic
hearts, was comparable (34±1.6% vs. 33±1.7%, respectively).
Infarct sizes of the nontransgenic hearts and transgenic hearts
were 15±0.5% and 9±0.5% of the LV, respectively. Infarct
sizes, expressed as the percentage of the area at risk for the
nontransgenic and transgenic hearts, were 44±2% and 30±2%,
respectively (Fig. 4B). Our results indicate that overexpression
of IAP-2 is able to limit the infarct size in an in vivo regional
ischemia model.
Cardiac troponin I release has been used as a marker for
cardiac injury. We did a pilot study to follow troponin I releaseFig. 2. Western blot analysis of IAP-1, IAP-2, and X-IAP. Heart homogenates of
nontransgenic and transgenic mice were probed with specific antibodies against
IAP-1, IAP-2, and XIAP. Actin antibody was included to check protein loading.
Fig. 3. Immunohistochemical staining of IAP-2 in hearts of nontransgenic and transgenic mice. Paraffin-embedded sections of nontransgenic and transgenic heart were
immunostained with an IAP-2 antibody. IAP-2 immunoreactivity (in red) was demonstrated by diffused cytoplasmic staining in the myocytes in panel B.
Magnification, ×200.
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5A, troponin I release significantly increased after 1 h of
reperfusion and reached a maximal level after 3–4 h. We next
compared troponin I level in the sera of nontransgenic andFig. 4. Protective effect of IAP-2 overexpression on myocardial infarction in
mice. Animals were subjected to 50 min of LAD coronary artery ligation
followed by 4 h of reperfusion. Panel A represents the TTC-staining pattern of
nontransgenic and transgenic hearts, respectively. Panel B shows an analysis of
the effect of IAP-2 overexpression on infarct sizes. Values are means±SE of 6
hearts. a=P<0.05 vs. nontransgenics.transgenic animals after 4 h of reperfusion. The total release of
cardiac troponin I of the nontransgenic and transgenic group
was 108±9 ng/ml and 64±9 ng/ml (P<0.05), respectively,
indicating a 1.7-fold reduction (Fig. 5B).
To examine whether the functional protection of the IAP-2
transgenic hearts is related to the anti-apoptotic property of IAP-
2, TUNEL analyses were performed on hearts subjected to
50 min of LAD ligation and 4 h of reperfusion. A representative
staining pattern is shown in Fig. 6A. Heart tissue from sham-
operated nontransgenic and transgenic mice exhibited low levels
of staining for TUNEL (1.8±0.45%, n=6) and (1.0±0.15%,
n=6), respectively (Fig. 6B). TUNEL-positive myocytes fromFig. 5. Release of cardiac troponin I. Mice were subjected to 50 min of LAD
coronary artery ligation followed by 4 h of reperfusion. Serum troponin I was
measured by an ELISA kit. Values represent means±SE. a=P<0.05 vs.
nontransgenics.
Fig. 6. Detection of apoptosis by the TUNEL procedure. Paraffin-embedded sections of nontransgenic and transgenic hearts subjected to 50 min of LAD coronary
artery ligation followed by 4 h of reperfusion were stained by TUNEL. Representative staining pattern of nontransgenic and transgenic hearts is shown in A. Arrows
indicate TUNEL-positive nuclei which were stained blue. Magnification, ×200. TUNEL-positive nuclei of myocytes were determined by random counting of 10 fields
per section. Each bar represents means±SE of six hearts. a=P<0.05, LAD ligation group in TG vs. NTG, b=P<0.05 vs. sham group (B).
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animals were (18.0±0.45%, n=6) and (10.0±2.0%, n=6,
P<0.05), respectively.
4. Discussion
There are two major types of anti-apoptotic proteins: Bcl-2
family proteins and IAPs. Previously, we reported that
overexpression of human Bcl-2 gene renders the mouse heart
more resistant to apoptosis and I/R injury [27]. In the present
study, we demonstrate that overexpression of IAP-2 confers
cardioprotection against I/R injury in vivo. In our study,
transgenic hearts had fewer TUNEL-positive cardiomyocytes
than nontransgenic hearts, suggesting that the cardioprotective
effect of IAP-2 is related to inhibition of cardiac apoptosis.
The finding that IAP-2 can protect the heart against I/R
injury is in line with previous studies on the IAP family. First,
IAP-2 level is known to be regulated by hypoxia [28]. Second,
overexpression of IAP-2 inhibits apoptosis induced by Fas and
serum withdrawal in several cell systems [25]. Finally, over-
expression of NIAP and XIAP in the brain reduces ischemic
damage in the rat hippocampus [29] and protects against the
toxicity of dopaminergic neurotoxin MPTP [30]. Our results are
also in agreement with previous studies that show that caspase
inhibition by general caspase inhibitors reduces infarct size and
inhibits apoptosis [31–33]. For example, Holly et al. [31]reported that systemic administration of a broad spectrum cas-
pase inhibitor partially attenuated caspase activation, decreased
TUNEL-positive myocytes, and reduced cardiac infarct size.
The mechanism of the cardioprotective effect of IAP-2 is not
clear, but there are a number of different possibilities. IAP-2
inhibits active caspases-3 and -7 and blocks the activation of
procaspase-9 [25]. In addition, IAP-2 can suppress caspase-8
activation [25,34,35]. These studies suggest that IAP-2
suppresses both intrinsic and extrinsic apoptotic pathways by
inhibiting specific caspases.
However, accumulating evidence indicates that IAPs can
inhibit apoptosis through mechanisms other than caspase
inhibition. First, IAPs can interact with TRAF-1 and TRAF-2
and play a role in type 2 TNF receptor signaling [36]. Second,
IAP-2 possesses a RING domain that functions as ubiquitin E3
ligase [37]. The degradation targets include caspases-3, -7, and
death-inducing protein SMAC (second mitochondria-derived
activator of caspases) [38–40]. Finally, IAP-2 may exert its
protective effect through the activation of NF-κB [41]. In short,
IAP-2's cardioprotective effect may be mediated by caspase
inhibition, protein degradation, and regulation of signaling
pathways. The precise mechanism of the cardioprotective effect
requires further investigation.
It is believed that there is significant interaction between the
IAP family members. For example, in XIAP deficient mice,
levels of IAP-1 and IAP-2 are increased [42]. In addition, IAP-1
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possible interactions between IAP family members, it is pos-
sible that in our transgenic mice, overexpression of IAP-2
affects other IAPs. However, our Western blot analysis demon-
strated that there were no alterations in the IAP-1 or XIAP levels
in the hearts of IAP-2 overexpressed mice (Fig. 2). This was
also confirmed by immunohistochemical staining (results not
shown).
One limitation of the present studies is that it does not
address whether reduction of infarct size in the IAP-2 hearts
correlates with improved cardiac function. We have shown
previously that overexpression of the anti-apoptotic protein Bcl-
2 reduced infarct sizes and improved cardiac function (27).
However, future studies will be needed to address whether this
is also true with IAP-2.
In summary, overexpression of IAP-2 protects the heart
against I/R injury and inhibits cardiac apoptosis. Though the
exact mechanism of these effects remains unclear, these findings
suggest that IAP overexpression strategies may be used to
prolong cardiomyocyte survival.
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